H.C. Wainwright raises Verastem stock price target to $20 on drug progress

H.C. Wainwright raised its price target on Verastem Inc. (VSTM) to $20 from $18, citing progress in its VS-7375 drug candidate. The stock trades at $9.38, with a consensus Buy rating. Verastem reported Q3 revenue of $24.01M, missing estimates but up 114% YoY. The company's gross profit margin is 87.6%.

Original reporting
Published Nov 6, 2026, 11:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$VSTM
Bullish
high confidence
Mentioned
$VSTM
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VSTMBullishMed
01

Why it matters

The analyst’s target raise reflects confidence in the pipeline, potentially outweighing the earnings miss in the short term.

02

Market read

New analyst target could trigger buying pressure in VSTM, with limited broader market impact.

03

What to watch

Execution risk on upcoming trial data and the modest size of the price‑target increase may temper price gains.

Relevance 7/10Novelty 7/10Timing: today

Background

Verastem reported a Q3 loss and revenue below estimates, but its pancreatic cancer candidate VS‑7375 is moving toward pivotal trials.

Company-level read

Ticker impact

$VSTMBullishHigh confidence
Context

H.C. Wainwright raised its price target on Verastem Inc. (VSTM) to $20 from $18 and maintained a Buy rating.

Expected impact

upward pressure as investors price in the higher target

Evidence & confidence

The new $20 target is a fresh analyst action that can prompt buying interest; no countervailing news was presented.

Market effects

Positive sentiment may spill over to other biotech firms developing KRAS‑targeted therapies.

Limited to U.S. biotech sector.

Minor, confined to investors tracking small‑cap oncology stocks.

Counterpoint

The recent Q3 earnings miss and revenue shortfall could limit upside despite the higher target.

Key entities

  • Verastem Inc.

    Biotech company developing KRAS‑mutant cancer therapies.

  • H.C. Wainwright

    Equity research firm that raised the price target.

Related articles

$VSTMMed

VSTM: 900 mg advances across indications, with three Phase III starts planned and a data-rich 2027 ahead

Verastem, Inc. (VSTM) is advancing its 900 mg dose of VS-7375 across multiple indications, focusing on selective target inhibition and chemo-free combinations. The company plans to initiate three Phase III trials and expects multiple clinical updates in 2027, with cash reserves lasting through the first half of 2028, according to its 8th Annual Wolfe Research Healthcare Conference.

$VSTMMedAI 8/10

What Verastem (VSTM) Said on Its Q3 Earnings Call

Verastem (VSTM) reported Q3 earnings, highlighting clinical trial data for VS-7375 in pancreatic, colorectal, and lung cancers. The company saw positive responses in early-stage trials and plans to initiate phase III trials. Verastem raised $250M in an October offering, ending Q3 with $422.8M in cash. The company expects to complete enrollment in some trials by year-end and in others by mid-2027.

$VSTMMedAI 8/10

Verastem (VSTM) Q3 2026 Earnings Call Transcript

Verastem (VSTM) reported Q3 2026 earnings, highlighting FDA acceptance of its new blister pack NDA with a February 2027 PDUFA date. The company shared positive clinical data for VS-7375 in pancreatic, colorectal, and lung cancers, raising $250M to fund operations into 2028. Q3 revenue for AVMAPKI FAKZYNJA CO-PACK was $24M, with plans to expand its use in approved indications. CEO Dan Patterson will step down at the end of 2026, succeeded by Michael Bailey.

$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.